NO20054791D0 - Forbindelser for behandling av stoffskiftesykdommer - Google Patents

Forbindelser for behandling av stoffskiftesykdommer

Info

Publication number
NO20054791D0
NO20054791D0 NO20054791A NO20054791A NO20054791D0 NO 20054791 D0 NO20054791 D0 NO 20054791D0 NO 20054791 A NO20054791 A NO 20054791A NO 20054791 A NO20054791 A NO 20054791A NO 20054791 D0 NO20054791 D0 NO 20054791D0
Authority
NO
Norway
Prior art keywords
carbon atoms
ring
alkyl
hydrogen
treatment
Prior art date
Application number
NO20054791A
Other languages
English (en)
Other versions
NO20054791L (no
Inventor
Reid W Von Borstel
Shalini Sharma
Kirvin L Hodge
Stephen D Wolpe
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of NO20054791D0 publication Critical patent/NO20054791D0/no
Publication of NO20054791L publication Critical patent/NO20054791L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20054791A 2003-04-15 2005-10-18 Forbindelser for behandling av stoffskiftesykdommer NO20054791L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46296003P 2003-04-15 2003-04-15
PCT/US2004/010799 WO2004091486A2 (en) 2003-04-15 2004-04-08 Compounds for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
NO20054791D0 true NO20054791D0 (no) 2005-10-18
NO20054791L NO20054791L (no) 2005-12-20

Family

ID=33300020

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054791A NO20054791L (no) 2003-04-15 2005-10-18 Forbindelser for behandling av stoffskiftesykdommer

Country Status (25)

Country Link
US (2) US7514555B2 (no)
EP (1) EP1633340B1 (no)
JP (2) JP4766693B2 (no)
KR (1) KR101127390B1 (no)
CN (2) CN1774244A (no)
AT (1) ATE487474T1 (no)
AU (1) AU2004229418B2 (no)
BR (1) BRPI0409469B1 (no)
CA (1) CA2521621C (no)
CY (1) CY1111310T1 (no)
DE (1) DE602004030004D1 (no)
DK (1) DK1633340T3 (no)
ES (1) ES2353601T3 (no)
HK (1) HK1084026A1 (no)
IL (1) IL171269A (no)
MX (1) MXPA05011042A (no)
NO (1) NO20054791L (no)
NZ (1) NZ542739A (no)
PL (1) PL1633340T3 (no)
PT (1) PT1633340E (no)
RU (1) RU2358722C2 (no)
SI (1) SI1633340T1 (no)
UA (1) UA80195C2 (no)
WO (1) WO2004091486A2 (no)
ZA (1) ZA200507704B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ530051A (en) * 2001-06-12 2006-12-22 Wellstat Therapeutics Corp Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders
EP1556085A4 (en) * 2002-11-01 2012-08-22 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
JP4697962B2 (ja) 2003-02-13 2011-06-08 ウェルスタット セラピューティクス コーポレイション 代謝性障害の処置のための化合物
PT1633340E (pt) * 2003-04-15 2011-02-22 Wellstat Therapeutics Corp Compostos para o tratamento de distúrbios metabólicos
DE602004024382D1 (de) 2003-04-22 2010-01-14 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
CA2522738C (en) * 2003-04-30 2011-11-08 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7906675B2 (en) * 2003-08-20 2011-03-15 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ATE540675T1 (de) 2005-04-01 2012-01-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
WO2007087505A2 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007087504A2 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR20080086523A (ko) 2006-01-25 2008-09-25 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
CA2639939A1 (en) 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2637884A1 (en) 2006-02-13 2007-08-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MX2008011022A (es) * 2006-02-28 2008-09-10 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
AU2007235145B2 (en) * 2006-03-31 2011-09-22 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
CN101437506A (zh) * 2006-05-18 2009-05-20 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
EP2026659A4 (en) * 2006-06-09 2010-06-30 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
MX2009001763A (es) * 2006-08-17 2009-02-25 Wellstat Therapeutics Corp Tratamiento combinado para trastornos metabolicos.
US8481595B2 (en) * 2008-01-15 2013-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
RU2501554C2 (ru) 2008-03-13 2013-12-20 Веллстат Терапьютикс Корпорейшн Соединения и способ снижения мочевой кислоты
WO2009137381A1 (en) * 2008-05-05 2009-11-12 Wellstat Therapeutics Corporation Synthesis of 4-[3-(2,6-dimethylbenzyloxy)phenyl]-4-oxobutanoic acid
EP2365746B1 (en) 2008-11-04 2014-07-16 Wellstat Therapeutics Corporation Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids
JP6458784B2 (ja) * 2016-08-03 2019-01-30 横河電機株式会社 駆動回路および電磁流量計

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048633A (en) 1960-12-02 1962-08-07 American Home Prod N-lower alkyl-2-(benzyloxatedphenyl)-glycolamide
GB1482195A (en) * 1973-08-23 1977-08-10 Beecham Group Ltd Biologically active phenyl(thio)ether derivatives
JPS57150633A (en) * 1981-03-14 1982-09-17 Nissan Chem Ind Ltd 4-benzyloxymandelic acid and its preparation
PL144053B1 (en) * 1983-01-31 1988-04-30 Lilly Co Eli Method of stimulating growth of domesticated animals,improving effectivness of food utilization ba domesticated animals and improving leanness of domesticated animals and fodder pre-mixture
JPS6261587A (ja) 1985-09-12 1987-03-18 Ajinomoto Co Inc 光学活性（ｒ）−ヒドロキシマンデル酸エステル中間体の製造法
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours
NZ231735A (en) 1988-12-23 1992-04-28 Ici Plc Alcohol/ether derivatives, preparation and pharmaceutical compositions thereof
JP3135936B2 (ja) 1991-06-10 2001-02-19 日新製鋼株式会社 アルミニウム含有ステンレス鋼のアルミニウム調整方法
WO1993014077A1 (en) 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5665387A (en) * 1994-09-01 1997-09-09 K.U. Leuven Research & Development Methods and compositions for primary and secondary prevention of autoimmune diabetes
FR2752422B1 (fr) 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
WO1999050254A1 (en) 1998-03-31 1999-10-07 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
CA2319495A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
DE19830770C1 (de) * 1998-07-09 2000-05-18 Sueddeutsche Kalkstickstoff Wasserlösliche Zinkpyruvate bzw. deren Hydrate, Verfahren zu ihrer Herstellung und deren Verwendung
NZ530051A (en) 2001-06-12 2006-12-22 Wellstat Therapeutics Corp Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders
JP4825375B2 (ja) 2001-08-28 2011-11-30 株式会社 資生堂 ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
EP1556085A4 (en) 2002-11-01 2012-08-22 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
JP4697962B2 (ja) 2003-02-13 2011-06-08 ウェルスタット セラピューティクス コーポレイション 代謝性障害の処置のための化合物
PT1633340E (pt) 2003-04-15 2011-02-22 Wellstat Therapeutics Corp Compostos para o tratamento de distúrbios metabólicos
DE602004024382D1 (de) 2003-04-22 2010-01-14 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
CA2522738C (en) 2003-04-30 2011-11-08 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7906675B2 (en) 2003-08-20 2011-03-15 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7163470B2 (en) 2004-06-25 2007-01-16 Callaway Golf Company Golf club head
ATE540675T1 (de) 2005-04-01 2012-01-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
WO2007087505A2 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR20080086523A (ko) 2006-01-25 2008-09-25 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물

Also Published As

Publication number Publication date
RU2005135441A (ru) 2006-03-20
BRPI0409469A (pt) 2006-04-18
EP1633340B1 (en) 2010-11-10
PT1633340E (pt) 2011-02-22
CN1774244A (zh) 2006-05-17
JP2006523696A (ja) 2006-10-19
EP1633340A4 (en) 2009-05-27
MXPA05011042A (es) 2005-12-15
BRPI0409469B1 (pt) 2016-04-26
US20060014784A1 (en) 2006-01-19
EP1633340A2 (en) 2006-03-15
DK1633340T3 (da) 2011-02-07
CA2521621C (en) 2011-11-01
PL1633340T3 (pl) 2011-04-29
JP4766693B2 (ja) 2011-09-07
DE602004030004D1 (de) 2010-12-23
UA80195C2 (en) 2007-08-27
CN101912380A (zh) 2010-12-15
ZA200507704B (en) 2007-02-28
IL171269A (en) 2011-09-27
HK1084026A1 (en) 2006-07-21
JP2011178808A (ja) 2011-09-15
JP5371062B2 (ja) 2013-12-18
AU2004229418B2 (en) 2008-07-31
KR20050121262A (ko) 2005-12-26
US20090156681A1 (en) 2009-06-18
US7973052B2 (en) 2011-07-05
RU2358722C2 (ru) 2009-06-20
SI1633340T1 (sl) 2011-02-28
ES2353601T3 (es) 2011-03-03
CY1111310T1 (el) 2015-08-05
NZ542739A (en) 2007-02-23
KR101127390B1 (ko) 2012-03-23
ATE487474T1 (de) 2010-11-15
CA2521621A1 (en) 2004-10-28
WO2004091486A3 (en) 2005-01-20
US7514555B2 (en) 2009-04-07
WO2004091486A2 (en) 2004-10-28
AU2004229418A1 (en) 2004-10-28
NO20054791L (no) 2005-12-20

Similar Documents

Publication Publication Date Title
NO20054791D0 (no) Forbindelser for behandling av stoffskiftesykdommer
HK1083460A1 (en) Compounds for the treatment of metabolic disorders
MXPA05008600A (es) Compuestos para el tratamiento de desordenes metabolicos.
HK1083462A1 (en) Compounds for the treatment of metabolic disorders
ATE530066T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
UA95613C2 (ru) Соединения для лечения расстройсв метаболизма
WO2007087505A3 (en) Compounds for the treatment of metabolic disorders
WO2007137008A3 (en) Compounds for the treatment of metabolic disorders
WO2007095462A3 (en) Compounds for the treatment of metabolic disorders
EP1868595A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
NO20003399D0 (no) <Alfa>-amionoamidderivater som er nyttige som smertestillende midler
WO2007087506A3 (en) Compounds for the treatment of metabolic disorders
UA88772C2 (ru) Соединения для лечения расстройств метаболизма
WO2007087504A3 (en) Compounds for the treatment of metabolic disorders
WO2007092729A3 (en) Compounds for the treatment of metabolic disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application